Soluble interleukin 2 receptors in patients with malignant lymphoma

D. S. Harrington, K. Patil, P. K. Lai, N. N. Yasuda, James Olen Armitage, S. H. Ip, D. D. Weisenburger, James Linder, D. T. Purtilo

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

We performed a retrospective analysis of serum interleukin 2 receptor (IL-2R) levels in a group of 35 patients with malignant lymphoma (ML; 13 T cell and 22 B cell) using a new enzyme immunoassay. Our objectives were to determine if elevated levels of soluble IL-2R occur in patients with active ML, whether serum IL-2R levels are prognostic, and whether prospective studies are warranted. Our preliminary data indicate that serum IL-2R levels correlate with disease activity and size of tumor, but not with grade or stage of the tumor. Five-year actuarial survival was 20% for patients with IL-2R levels greater than 1000 U/mL at any time during their course and 86% for patients who did not exceed that threshold. Furthermore, patients with IL-2R levels lower than 1000 U/mL were more likely to achieve a complete remission. Serum lactate dehydrogenase and uric acid levels did not show significant correlation with disease activity or prognosis. We conclude that serum IL-2R levels may have clinical and prognostic significance in patients with ML and that prospective studies are indicated.

Original languageEnglish (US)
Pages (from-to)597-601
Number of pages5
JournalArchives of Pathology and Laboratory Medicine
Volume112
Issue number6
StatePublished - Jan 1 1988

Fingerprint

Interleukin-2 Receptors
Lymphoma
Serum
Prospective Studies
Uric Acid
Immunoenzyme Techniques
L-Lactate Dehydrogenase
Neoplasms
B-Lymphocytes
T-Lymphocytes
Survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Harrington, D. S., Patil, K., Lai, P. K., Yasuda, N. N., Armitage, J. O., Ip, S. H., ... Purtilo, D. T. (1988). Soluble interleukin 2 receptors in patients with malignant lymphoma. Archives of Pathology and Laboratory Medicine, 112(6), 597-601.

Soluble interleukin 2 receptors in patients with malignant lymphoma. / Harrington, D. S.; Patil, K.; Lai, P. K.; Yasuda, N. N.; Armitage, James Olen; Ip, S. H.; Weisenburger, D. D.; Linder, James; Purtilo, D. T.

In: Archives of Pathology and Laboratory Medicine, Vol. 112, No. 6, 01.01.1988, p. 597-601.

Research output: Contribution to journalArticle

Harrington, DS, Patil, K, Lai, PK, Yasuda, NN, Armitage, JO, Ip, SH, Weisenburger, DD, Linder, J & Purtilo, DT 1988, 'Soluble interleukin 2 receptors in patients with malignant lymphoma', Archives of Pathology and Laboratory Medicine, vol. 112, no. 6, pp. 597-601.
Harrington DS, Patil K, Lai PK, Yasuda NN, Armitage JO, Ip SH et al. Soluble interleukin 2 receptors in patients with malignant lymphoma. Archives of Pathology and Laboratory Medicine. 1988 Jan 1;112(6):597-601.
Harrington, D. S. ; Patil, K. ; Lai, P. K. ; Yasuda, N. N. ; Armitage, James Olen ; Ip, S. H. ; Weisenburger, D. D. ; Linder, James ; Purtilo, D. T. / Soluble interleukin 2 receptors in patients with malignant lymphoma. In: Archives of Pathology and Laboratory Medicine. 1988 ; Vol. 112, No. 6. pp. 597-601.
@article{1a2e02126a0e4e18ae827771dd8b497f,
title = "Soluble interleukin 2 receptors in patients with malignant lymphoma",
abstract = "We performed a retrospective analysis of serum interleukin 2 receptor (IL-2R) levels in a group of 35 patients with malignant lymphoma (ML; 13 T cell and 22 B cell) using a new enzyme immunoassay. Our objectives were to determine if elevated levels of soluble IL-2R occur in patients with active ML, whether serum IL-2R levels are prognostic, and whether prospective studies are warranted. Our preliminary data indicate that serum IL-2R levels correlate with disease activity and size of tumor, but not with grade or stage of the tumor. Five-year actuarial survival was 20{\%} for patients with IL-2R levels greater than 1000 U/mL at any time during their course and 86{\%} for patients who did not exceed that threshold. Furthermore, patients with IL-2R levels lower than 1000 U/mL were more likely to achieve a complete remission. Serum lactate dehydrogenase and uric acid levels did not show significant correlation with disease activity or prognosis. We conclude that serum IL-2R levels may have clinical and prognostic significance in patients with ML and that prospective studies are indicated.",
author = "Harrington, {D. S.} and K. Patil and Lai, {P. K.} and Yasuda, {N. N.} and Armitage, {James Olen} and Ip, {S. H.} and Weisenburger, {D. D.} and James Linder and Purtilo, {D. T.}",
year = "1988",
month = "1",
day = "1",
language = "English (US)",
volume = "112",
pages = "597--601",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "6",

}

TY - JOUR

T1 - Soluble interleukin 2 receptors in patients with malignant lymphoma

AU - Harrington, D. S.

AU - Patil, K.

AU - Lai, P. K.

AU - Yasuda, N. N.

AU - Armitage, James Olen

AU - Ip, S. H.

AU - Weisenburger, D. D.

AU - Linder, James

AU - Purtilo, D. T.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - We performed a retrospective analysis of serum interleukin 2 receptor (IL-2R) levels in a group of 35 patients with malignant lymphoma (ML; 13 T cell and 22 B cell) using a new enzyme immunoassay. Our objectives were to determine if elevated levels of soluble IL-2R occur in patients with active ML, whether serum IL-2R levels are prognostic, and whether prospective studies are warranted. Our preliminary data indicate that serum IL-2R levels correlate with disease activity and size of tumor, but not with grade or stage of the tumor. Five-year actuarial survival was 20% for patients with IL-2R levels greater than 1000 U/mL at any time during their course and 86% for patients who did not exceed that threshold. Furthermore, patients with IL-2R levels lower than 1000 U/mL were more likely to achieve a complete remission. Serum lactate dehydrogenase and uric acid levels did not show significant correlation with disease activity or prognosis. We conclude that serum IL-2R levels may have clinical and prognostic significance in patients with ML and that prospective studies are indicated.

AB - We performed a retrospective analysis of serum interleukin 2 receptor (IL-2R) levels in a group of 35 patients with malignant lymphoma (ML; 13 T cell and 22 B cell) using a new enzyme immunoassay. Our objectives were to determine if elevated levels of soluble IL-2R occur in patients with active ML, whether serum IL-2R levels are prognostic, and whether prospective studies are warranted. Our preliminary data indicate that serum IL-2R levels correlate with disease activity and size of tumor, but not with grade or stage of the tumor. Five-year actuarial survival was 20% for patients with IL-2R levels greater than 1000 U/mL at any time during their course and 86% for patients who did not exceed that threshold. Furthermore, patients with IL-2R levels lower than 1000 U/mL were more likely to achieve a complete remission. Serum lactate dehydrogenase and uric acid levels did not show significant correlation with disease activity or prognosis. We conclude that serum IL-2R levels may have clinical and prognostic significance in patients with ML and that prospective studies are indicated.

UR - http://www.scopus.com/inward/record.url?scp=0023887590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023887590&partnerID=8YFLogxK

M3 - Article

VL - 112

SP - 597

EP - 601

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 6

ER -